东瑞制药2024中期报告

Corporate Information2Group Structure4Financial Highlights5Management Discussion and Analysis6Other Information20Condensed Consolidated Statement of Profit or Loss27Condensed Consolidated Statement of Comprehensive Income28Condensed Consolidated Statement of Financial Position29Condensed Consolidated Statement of Changes in Equity31Condensed Consolidated Statement of Cash Flows33Notes to the Interim Financial Information37 Corporate Information BOARD OF DIRECTORS EXECUTIVE DIRECTORSMs. LI Kei Ling(Chairman)Mr. HUNG Yung Lai NON-EXECUTIVE DIRECTORMr. LEUNG Hong Man EDE, Ronald Hao Xi INDEPENDENT NON-EXECUTIVE DIRECTORS Mr. LO Tung Sing TonyMr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan CHIEF EXECUTIVE OFFICER Mr. WU Weixian AUDIT COMMITTEE EDE, Ronald Hao Xi Mr. LO Tung Sing Tony(Chairman)Mr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan REMUNERATION COMMITTEE Mr. EDE, Ronald Hao Xi(Chairman)Ms. LI Kei LingMr. LO Tung Sing TonyMs. LAM Ming Yee Joan EDE, Ronald Hao Xi NOMINATION COMMITTEE EDE, Ronald Hao Xi Ms. LI Kei Ling(Chairman)Mr. LO Tung Sing TonyMr. EDE, Ronald Hao XiMs. LAM Ming Yee Joan AUDITORS Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED東瑞製葯（控股）有限公司0 2 PRINCIPAL BANKERS Bank of China (Hong Kong) Limited, Hong KongThe Hongkong and Shanghai Banking Corporation Limited, Hong KongIndustrial and Commercial Bank of China Suzhou Wuzhong Sub-BranchAgricultural Bank of China Suzhou Nanmen Sub-BranchBank of China Suzhou Wuzhong Sub-Branch HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS 338303001–02 Units 3001–02, 30/F, CNT Tower, 338 Hennessy Road,Wanchai, Hong Kong REGISTERED OFFICE Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins Drive, P.O. Box 2681,Grand Cayman KY1-1111,Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins Drive, P.O. Box 2681,Grand Cayman KY1-1111,Cayman Islands HONG KONG BRANCH SHARE REGISTRAR ANDTRANSFER OFFICE 1617 Tricor Abacus Limited17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong SHAREHOLDER’S CALENDAR Closure of Register of Members for Interim DividendWednesday, 18 September 2024 to Friday, 20 September 2024(both days inclusive) Record Date to determine Shareholder’s entitlement to theInterim DividendFriday, 20 September 2024 0 3INTERIM REPORT 2024二零二四年中期報告0.015 Interim Dividend, payableHK$0.015 per share, payable on or about 3 October 2024 Group Structure The board (the “Board”) of directors (the “Directors”) of DawnraysPharmaceutical(Holdings)Limited(the“Company”)is pleased toannounce the unaudited consolidated interim results of the Companyandits subsidiaries(collectively,the“Group”)for the six monthsended30 June 2024(the“period”)together with the comparativefigures for the corresponding period in 2023. These interim resultshave been reviewed by the audit committee of the Company. Management Discussion and Analysis RESULTS 577,447,000649,920,00011.2%493,046,000255,941,00092.6%35%277,627,000286,670,00089,292,000105,049,000366,919,000126,127,000139,957,00013,830,0009.9% TheGroup recorded revenue of approximately RMB577,447,000for the six months ended 30 June 2024 (2023: RMB649,920,000),representinga decrease of approximately 11.2%as compared tothe same period of 2023. Profit attributable to owners of the parentwasapproximately RMB493,046,000(2023:RMB255,941,000),representingan increase of approximately 92.6%as compared tothe same period of 2023. The increase in profit for the period wasmainly attributable to the net gain of approximately RMB277,627,000(before tax RMB286,670,000) from the disposal of the Group’s 35%equityinterest in AD Pharmaceuticals Co.,Ltd.with nil carryingvalue, and the net gain of approximately RMB89,292,000 (before taxRMB105,049,000) from the government subsidy for the verificationofthe equipment in the factory on Tianling Road.Excluding theabovenon-recurring profit of approximately RMB366,919,000,recurring profit attributable to owners of the parent for the first halfof 2024 amounted to approximately RMB126,127,000, representingadecrease of approximately RMB13,830,000 or by 9.9%ascomparedto approximately RMB139,957,000 for the same periodof 2023, which was mainly due to the relocation of Tianling Roadfactoryof Suzhou Dawnrays Pharmaceutical Co.,Ltd.(“SuzhouDawnrays”), the construction of a new factory of Lanzhou DawnraysPharmaceutical Co., Ltd.(“Lanzhou Dawnrays”),the impact of thecentralized procurement of “Anneixi” and the increase in research anddevelopment expenses of the new research institute. INDUSTRY ENVIRONMENT In the first half of 2024, the pharmaceutical industry continued tomakesteady progress in the transformation and upgrading in thepost-pandemic era. Driven by various factors such as